A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients

Trial Profile

A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Roxadustat (Primary) ; Epoetin alfa
  • Indications Anaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ROCKIES
  • Sponsors AstraZeneca
  • Most Recent Events

    • 23 Mar 2018 Planned End Date changed from 2 Apr 2018 to 25 Sep 2018.
    • 23 Mar 2018 Planned primary completion date changed from 2 Apr 2018 to 25 Sep 2018.
    • 13 Dec 2017 Planned number of patients changed from 2100 to 2070.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top